All Stories

  1. HCV NS5A replication complex inhibitors
  2. Making a good drug better
  3. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A
  4. Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
  5. HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity
  6. Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir
  7. A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir
  8. Characterizations of HCV NS5A replication complex inhibitors
  9. HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives
  10. HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies
  11. HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides
  12. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052
  13. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
  14. Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes
  15. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
  16. Multiplexing cell based assays
  17. Functional Conservations of the Alkaline Nuclease of Herpes Simplex Type 1 and Human Cytomegalovirus
  18. Identification of a Novel Peptide Substrate of HSV-1 Protease Using Substrate Phage Display
  19. Stimulation of the Herpes Simplex Virus Type I Protease by Antichaeotrophic Salts
  20. The Effect of Internal Autocleavage on Kinetic Properties of the Human Cytomegalovirus Protease Catalytic Domain
  21. Substrate requirements of the HSV-1 and CMV proteases in vitro using peptides derived from their maturation and release sites
  22. In vitro Proteolytic Activity and Active-Site Identification of the Human Cytomegalovirus Protease
  23. 67 Identification of the specific serine residue at the active site of the herpes simplex virus type 1 protease
  24. Restriction Endonuclease Patterns of Cytomegalovirus After Passage in Humans